Seeking in-licensing assets | Email: BD@drugtimes.cn
For global biotech search & evaluation professionals, Amgen’s decades-proven business development framework sets a clear blueprint for win-win cross-border innovation partnerships—an approach DrugTimes BD Team leverages to connect Chinese biotech innovators with global pharma, biotech and VC players.
Founded in 1980 by venture capitalists and genetics scientists, Amgen evolved from a VC-backed startup into one of the world’s largest independent biotech enterprises. Its unmatched late-stage pipeline, diversified marketed assets and global footprint rest on core technical strengths spanning human genetics, protein engineering, biologic manufacturing and full-spectrum clinical development. This deep internal capability base makes Amgen an ideal licensing, co-development and investment partner, a logic DrugTimes BD Team applies to match China’s innovative asset owners with overseas counterparts.
Central to Amgen’s sustained growth is its balanced innovation sourcing strategy. The firm equally prioritizes in-house R&D and external pipeline in-licensing, driving breakthrough therapies across oncology, cardiovascular disease, inflammation, nephrology, neuroscience and rare bone disorders. Similarly, DrugTimes BD Team’s core value lies in bridging two innovation ecosystems: we source novel preclinical and clinical-stage assets from Chinese biotechs, and surface them to global search & evaluation teams seeking differentiated candidates to fill pipeline gaps.
Amgen rejects rigid, one-size-fits-all transaction frameworks, adopting bespoke, flexible deal structuring to unlock asset value. Its track record covers spin-outs, limited partnership VC investments, equity stakes, research collaborations, joint ventures, in/out licensing, early-stage alliances and full M&A. This full-spectrum transaction toolkit aligns perfectly with DrugTimes BD Team’s service portfolio: we facilitate $1B+ global licensing and NewCo formation deals, having closed two cross-border transactions each exceeding $1 billion in total consideration to date.
What separates Amgen’s partnerships from industry peers is its end-to-end alliance management system, covering every phase from term sheet negotiation to commercial implementation. With over 30 years of experience partnering with hundreds of biotech and VC firms—from early research platforms to multi-billion-dollar commercial products—its dedicated partnership team maintains streamlined communication across internal functional groups to maximize shared value. Mirroring this model, DrugTimes BD Team delivers full-lifecycle transaction support: we coordinate cross-functional due diligence, align term sheet priorities for Chinese and Western stakeholders, and sustain post-deal alliance communication to safeguard long-term partnership success.
For global S&E specialists hunting high-potential Chinese novel drug assets, DrugTimes BD Team acts as your trusted local liaison. Reach out via email to access curated, de-risked innovation project pipelines, and let our team match your strategic pipeline priorities with China’s most promising biotech candidates.
【Disclaimer】All content featured on this website is provided solely for informational reference and does not constitute investment, legal or commercial advice. No warranty, express or implied, is made regarding the accuracy, integrity or timeliness of any information herein. Any reliance placed on such materials shall be at the user’s own risk. We assume no liability for any losses arising from use of the website content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
